未知生产厂商
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute myeloid leukemia, B-cell lymphoma, and solid tumors in combination with other compounds. It is also a potential therapy for COVID-19.
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute myeloid leukemia, B-cell lymphoma, and solid tumors in combination with other compounds. It is also a potential therapy for COVID-19.
FT516 contains engineered NK cells expressing CD16, which are activated through binding of the Fc portion of IgG antibodies. When activated, these NK Cells destroy antibody-coated target cells while also secreting additional cytokines and recruiting T-cells. The mechanism, referred to as antibody-dependent cellular cytotoxicity (ADCC), depends on the stable and effective expression of CD16 on the NK cells.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
